FDA Approves Gefurulimab as First Once-Weekly, Self-Administered C5 Inhibitor for gMG
The FDA approved gefurulimab (Klygefa) by Alexion, a unit of AstraZeneca, for treating generalized myasthenia gravis (gMG) in adults. It is the first once-weekly, self-administered C5 inhibitor. The approval is based on the PREVAIL trial, showing significant improvements in daily living and disease scores. The drug was generally well-tolerated, with common side effects including injection site reactions.
How this was made

The 30-second read
Why it matters
The FDA approval is based on the PREVAIL Phase 3 trial meeting primary and key secondary endpoints (MG-ADL and QMG improvements) with a safety profile consistent with other C5 inhibitors, plus a differentiated dosing and administration model.
Market read
Traders can treat this as a pipeline validation event for AstraZeneca’s neurology franchise, with differentiation from IV C5 inhibitors via weekly autoinjector dosing.
What to watch
Complement inhibitors carry meningococcal infection risk and vaccination requirements; uptake and payer coverage could be constrained by logistics and risk-management burden despite the autoinjector convenience.
Background
Gefurulimab (Klygefa) is a dual-binding nanobody that blocks C5 and is designed for once-weekly self-administration via autoinjector in AChR-antibody-positive generalized myasthenia gravis.
Ticker impact
FDA approval of gefurulimab (Klygefa) as the first once-weekly, self-administered C5 inhibitor for AChR-positive gMG is a direct regulatory milestone for AstraZeneca.
Likely positive bias as investors price in expanded addressable market and differentiation versus IV C5 inhibitors.
The article is a first-in-class FDA approval with pivotal Phase 3 efficacy and a clear administration advantage, which typically improves perceived commercial prospects even without revenue guidance.
Market effects
Reinforces competitive momentum in complement inhibition for autoimmune neuromuscular disease, highlighting a shift toward patient-administered regimens.
US regulatory approval can drive broader global sentiment for complement-inhibitor franchises.
May influence how investors value C5-inhibitor platforms internationally, given the once-weekly autoinjector differentiation.
Counterpoint
Efficacy and safety are supportive, but the article provides no commercial uptake, pricing, or guidance, so near-term stock impact may fade without follow-on data on real-world adoption.
Key entities
- drugGefurulimab (Klygefa)
First once-weekly, self-administered C5 inhibitor for AChR-positive generalized myasthenia gravis, approved by the FDA.
- companyAstraZeneca
Co-developer/marketer of gefurulimab; approval reported via company references in the article.
- clinical_trialPREVAIL trial
Global Phase 3 randomized, double-blind, placebo-controlled study supporting the approval.
- regulatory_guidanceCDC meningococcal guidance
Highlights elevated meningococcal disease risk and vaccination recommendations for complement inhibitor patients.



